ATR · AptarGroup, Inc.

AptarGroup's first quarter 2026 results reflected a mixed operational performance, with reported sales growth of 11% to $982.9 million masking flat core sales growth. The disparity was driven by significant currency tailwinds and acquisition contributions, particularly in the Beauty segment, which offset a 1% core sales decline in the Pharma segment. Adjusted EBITDA margin contracted 150 basis points to 19.2%, pressured by unfavorable product mix and isolated operational disruptions. The Pharma segment faced headwinds from anticipated emergency medicine destocking, resulting in a 10% sales decline in the prescription division, though this was partially mitigated by strong double-digit growth in the injectables division driven by GLP-1 therapies and biologics demand. The Beauty segment delivered 19% reported sales growth, supported by fragrance and personal care applications, while the Closures segment saw margin compression due to maintenance issues and weather-related plant closures. Management provided Q2 2026 adjusted EPS guidance of $1.32 to $1.40, signaling an expected return to healthy growth in the prescription division outside of emergency medicine. In a significant leadership transition, the company announced Gael Touya will assume the role of CEO on September 1, 2026, replacing Stephan B. Tanda. Capital allocation remained active, with $131 million returned to shareholders through dividends and share repurchases during the quarter.